Evofem Biosciences, Inc. Net Income Loss

• Evofem Biosciences, Inc. showed a decrease of -116.7% in Net Income Loss from 2023 to 2024.
• This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
• XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$6.03 million | Q2 2016: -$2.66 million | Q3 2016: -$2.36 million | Q1 2017: -$5.27 million | Q2 2017: -$6.51 million | Q3 2017: -$74.03 million | Q4 2017: -$19.49 million | Q1 2018: -$69.06 million | Q2 2018: -$23.24 million | Q3 2018: -$18.43 million | Q4 2018: -$14.98 million | Q1 2019: -$18.07 million | Q2 2019: -$35.45 million | Q3 2019: -$13.80 million | Q4 2019: -$12.72 million | Q1 2020: -$19.15 million | Q2 2020: -$52.67 million | Q3 2020: -$29.90 million | Q1 2021: -$46.15 million | Q2 2021: -$33.43 million | Q3 2021: -$74.06 million | Q1 2022: -$31.89 million | Q2 2022: -$125.98 million | Q3 2022: $89.51 million | Q1 2023: -$2.35 million | Q2 2023: -$8.56 million | Q3 2023: $66.01 million | Q1 2024: -$4.81 million | Q2 2024: $1.35 million | Q3 2024: -$2.37 million | Q1 2025: $956.0 thousand | Q2 2025: -$1.78 million | Q3 2025: -$1.57 million.
• Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Net Income Loss has grown by 41.0%.
• Historical annual values: Fiscal year 2024: -$8.86 million | Fiscal year 2023: $52.98 million | Fiscal year 2022: -$76.70 million | Fiscal year 2021: -$205.19 million | Fiscal year 2020: -$142.31 million | Fiscal year 2019: -$80.03 million | Fiscal year 2018: -$125.71 million | Fiscal year 2017: -$105.31 million | Fiscal year 2016: -$13.02 million | Fiscal year 2015: -$43.16 million | Fiscal year 2014: -$10.82 million | Fiscal year 2013: -$15.02 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026